The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
This makes VLCC the sole institution in the country authorised to conduct in-person NCLC exams
The innovative eyedrop targets inflammation and pain following ocular surgery
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Under the agreement, Apotex’s branded division, Searchlight Pharma, will seek regulatory approval and handle marketing and distribution in Canada
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
Subscribe To Our Newsletter & Stay Updated
